|Articles|May 26, 2023
Discussing Rapid Accurate mRNA Potency Assay Possibilities with Sean Hart
Author(s)Chris Spivey
Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.
Advertisement
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on the topic of rapid accurate mRNA potency assay possibilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Developing Next-Gen Cell Lines Using Targeted Integration
2
FAQ: What You Need to Know about the Current Antibody Pipeline
3
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
4
FAQ: What Precision Analytics Have Done to Advance Next-Gen Biologics
5